SkQ1 is the first mitochondria-targeted antioxidant to reach clinical phase of development for an ophthalmic indication
U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc.
Communication and proper preparation are necessary for a successful study.
Data may influence prescribing habits and formulary availability in future allergy seasons